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Summary.-Double-antibody radioimmunoassay using a mouse monoclonal anti-
CEA (MA/1) has been used to measure CEA in human serum. Low levels of MA/1-
binding CEA have been found in serum from normal individuals and moderately
raised levels are sometimes associated with certain non-malignant diseases. As with
conventional anti-CEA, the MA/i antibodies can recognize significant amounts of
CEA in serum from patients with a variety of solid tumours. However they appear
to recognize a different immunodeterminant and possibly a different population of
CEA molecules to, or a subset of, those measured by two routine assays. Studies in
which the MA/i assay was directly compared with the results of the Charing Cross
routine and Abbott EIA assays have indicated that different immunological forms
ofCEA may be expressed in the course oftumour progression but no prognostic value
was evident in this study. Our results stress the need to resolve immunological
specificities expressed by CEA-like molecules and evaluate their clinical importance.
SOMATIC-CELL HYBRIDIZATION, as used
by Kohler & Milstein (1975), has proved
to be a powerful tool for the in vitro
production of specific monoclonal anti-
bodies. The method has proved entirely
successful for the production of antibodies
to cell-surface antigens (Trucco et al.,
1978) and viruses (Koprowski et al.,
1977). It may also have great potential in
the field of secreted tumour markers and
monoclonal antibodies against CEA
(Accolla et al., 1979; Rogers et al., 1981),
HCG (Stahli et al., 1980) and a-foeto-
protein (Tsung et al., 1980) have been
described.
Monoclonal anti-CEA antibodies are of
particular interest since they promise to
overcome many of the difficulties of con-
ventional sera. The need for extensive
absorption of antibodies to normal com-
ponents and to cross-reactive antigens
before use in clinical radioimmunoassay
would be eliminated, and there is the
possibility of defining CEA and associated
molecular forms more precisely. Moreover
monoclonal antibodies should provide
reagents with which to test the concept
that different immunological forms of
CEA could be expressed by different
diseases (Rogers, 1976).
The major limitations of CEA assays in
their present forms are: (1) failure to
detect and monitor subelinical cancer,
(2) failure to discriminate between cancer
and certain non-malignant diseases, and
(3) the variation in numerical values for
CEA obtained with different assay systems
(Vrba et al., 1975).
We have recently reported monoclonal
antibodies against CEA isolated from liver
metastases of colonic tumour, and have
determined conditions under which radio-
immunoassay of CEA in human sera could
be carried out (Rogers et al., 1980, 1981).
This paper describes the use of a radio-
immunoassay using a monoclonal anti-
body, MA/I, to measure CEA in human
serum, and reports preliminary results on
the assessment of sera from normal sub-
jects and patients with a variety of malig-G. T. ROGERS ET AL.
nant and non-malignant diseases, a com-
parative study on colo-rectal and gastric
cancer in which MA/i assay values are
compared with two CEA assays using
heterologous antisera, and serial CEA
measurements on patients with colo-
rectal cancer as determined by the mono-
clonal assay and the two conventional
assays. A part of this work has already
been reported by Rogers et al. (1980).
MATERIALS AND METHODS
Patients' serum samples.-Serum samples
from normal individuals were taken from
hospital personnel and medical students in
the age group 19-40 years. Samples from
patients with non-malignant disease were
obtained from the Department of Pathology,
Charing Cross Hospital. Other samples were
taken from our sample bank, and composed
of sera from patients routinely assessed for
CEA and known to have malignant disease.
Longitudinal studies were made on patients
attending follow-up clinics following the
resection of a primary colonic or rectal
cancer. Unless otherwise stated, patients re-
ported as having no evidence of recurrence
throughout the period of study remained
tumour-free for at least 6 months after the
study had been completed.
Assays for CEA.-The monoclonal MA/I
assay was adapted to make use ofthe filtering
and computing capabilities of the Kemtek
3000 automated RIA machine, though the
assays were set up manually using standard
dispensing equipment and 3ml polystyrene
tubes. Samples and standards were assayed
in triplicate by using 100 ,ul of test serum or
CEA standards in assay buffer (phosphate-
buffered saline 40 mM; EDTA 8 mM; bovine
serum albumin, 1 g/l; thiomersal 20 mM,
pH 7). One hundred 1I of assay buffer was
added to each serum sample and 100 ,lI of
normal pooled serum (NPS) added to the
standards. Fifty [lI of monoclonal anti-CEA
diluted 1:1000 and 50 1ul of 1251-labelled
CEA were then added to each tube. At the
same time zero-antigen tests were set up in
which 100 ,lI of assay buffer was added in
place of the CEA standard. Nonspecific
binding was determined by setting up tubes
in which 50 lI of 125I-CEA, 150 ,l of assay
buffer and 100 jul of NPS were added. All
tubes were incubated for 16 h at 37°C. and
then 50 ,ul of rabbit anti-mouse Ig diluted
1:40 was added. (The rabbit anti-mouse
serum was obtained from Dako, Product
Z109 Batch O1OA.) After a further 4 h at
room temperature, the contents of each tube
were filtered on to fibre-glass discs carried on
the film of the Kemtek 3000. After washing
and drying each disc was counted for 1251.
The counting data were then fed to the micro-
processor ofthe Kemtek 3000 to perform pre-
programmed calculations. The concentration
of CEA in each sample was calculated in
units/ml by interpolation from the standard
line. The standard line was based on a log-
logit plot from counting data on the zero-
antigen tests, the n.s.b. determination and
from 9 CEA standards obtained by making
sequential 2-fold dilutions from a 1000u/ml
CEA standard (R41) (see Rogers et al., 1980).
The clinical cut-off chosen was 15 u/ml so
that > 15 u/ml was regarded as abnormal.
The Charing Cross routine assay using a
conventionally prepared primary antiserum,
PK1G (goat) raised to CEA Con A fraction
2B (R42) and absorbed with normal human
spleen and normal human serum, was a
double-antibody system similar to that
described above. Samples were assayed
directly without prior extraction. Precipi-
tation of the CEA-anti-CEA complexes was
achieved by using a second antibody (BW 402
horse anti-goat+sheep). CEA isolated by
perchloric acid extraction and purification on
Sepharose 6B and Sephadex G-200 (Prepara-
tion M12) was used as standard. CEA values
below 10 ng/ml are regarded as normal. The
normal range was determined by measuring
300 samples from patients with non-malig-
nant diseases.
The Abbott EIA system was a solid-phase
diagnostic immunoassay based on the sand-
wich principle (Oehr et al., 1980). CEA pre-
sent in the serum sample was extracted by
heating in buffer (pH 5) at 85°C for 10 min.
After centrifuging, the supernatants were
assayed by binding the CEA to beads coated
with guinea-pig anti-CEA. After washing,
the beads were incubated with goat anti-
CEA conjuaged with horseradish peroxidase.
Colour intensity produced from the reaction
of the enzyme with its substrate was meas-
ured, and the CEA (ng/ml) determined from
the standard curve.
Radiolabelled CEA.-CEA Con A Fraction
2B (R42) was labelled with 1251 (IMS 30,
Radiochemical Centre, Amersham) by a modi-
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fication of the Chloramine T technique
(Greenwood et al., 1963). Free iodine was
removed by gel filtration on Sephadex G-200,
and each fraction corresponding to the pro-
tein peak assessed for binding to the PK1G
antiserum. The two fractions giving the
highest binding of total counts added were
pooled and used in the radioimmunoassay. A
dilution giving 80,000 counts in 50 IlI was
used for the Charing Cross routine assay and a
1:200 dilution of the pooled label proteins
corresponding to about 120,000 counts in
50 pl used for the MA/1 assay. The specific
activity of the label (179 ,aCi/,g) was deter-
mined from the "self-displacement" analysis
by the interpolated dose of the binding of
several dilutions of label from the standard
curve.
Reagents.-CEA (M-12) was isolated from
a pool of 6 liver metastases of colonic tumour
by perchloric acid extraction and chromato-
graphy on Sepharose 6B and Sephadex
G-200, according to the method of Coligan
et al. (1972). CEA-2B (R42) was prepared
from a different pool of 6 liver metastases, as
described above, and further purified on a
column of Con A-Sepharose as previously
described (Rogers et al., 1976). The CEA
standard (R41) was isolated from 6 additional
specimens, as described for preparation R42.
Units used in the MA/I assay.-Because
of the poor inhibition by standard CEA pre-
parations, an arbitrary unit has been adopted
for use in the monoclonal MA/I assay
(Rogers et al., 1981). Thus 100 u of MA/1-
binding CEA is defined as that amount pro-
ducing 50% displacement of bound label. In
the case of the CEA standard (R41) 8600
ng/ml of CEA, as mneasured on the Charing
Cross PK1G assay, was required for 50%
displacement, and the top standard used was
43,000 ng/ml.
RESULTS
An upper normal cut-off of 15 u/mI for
the MA/I assay was tentatively chosen on
the basis of the assay results obtained
with 144 sera from normal individuals
and 200 sera from patients with various
non-malignant diseases. Values > 15 u/ml
were regarded as pathological. Of the
normal sera, only 1 was > 15 u/ml, and
27 were 5-15 u/ml (Table I). Preliminary
assessment of the sera from patients with
a variety of non-malignant disease shows
5% of 161 raised if chronic renal failure
was excluded (Table I). 25% ofsamples in
the non-malignant group were in the range
5-15 u/ml and 70% below 5 u/ml. Of the
5% > 15 u/ml 2 were diabetic patients
(23-5 and 25 u/ml), 2 had left ventricular
failure (19.1 and 17-5 u/ml), one had un-
diagnosed chest pain (25 u/ml) and 2 had
deep-vein thrombosis (29.3 and 18-6 u/mI).
In another group of 43 patients with selec-
ted non-malignant disease, including
chronic pancreatitis and hepatic cirrhosis,
there were 5 with raised values (Table I).
33% of 40 samples from patients with
chronic renal failure on the other hand
were raised on the MA/I assay, with values
ranging from 15 to 55 u/ml (mean 24.5)
(Table I).
Earlier studies (Rogers et al., 1981) on
the competitive binding of MA/I have
shown that 8,600 ng/ml of unlabelled
CEA, extracted with perchloric acid from
tumour tissue, was required to produce
500o inhibition of bound label, whereas
only 30 ng/ml of CEA similarly extracted
from patients' sera was required to pro-
TABLE I.-Frequency of raised levels of MA/I-binding CEA in the serum of normal
subjects and patients with non-malignant disease
(u/ml)
r ~~~~~As
Group
Normal subjects
Non-malignant, excluding
chronic renal failure
Chronic renal failure
Chronic pancreatitis
Cirrhosis
Gastric and duodenal ulcer
Hepatitis
Gastritis
No. <5
144 116
161
40
14
8
10
5
6
110
13
8
3
8
3
3
5-15 15-20
27
42
15
4
3
1
2
2
6
4
1
1
% Raised
>20 (>15u/ml)
1 0-7
3
9
1
5
33
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TABLE II.-Frequency of raised levels of MA/1-bindinq CEA in the serum of cancer
patients
Location of
tumour
Rectum
Colon
Stomach
Breast
Prostate
Lung
Ovary
Teratoma
Choriocarcinoma
No. r
patients
95
102
72
92
34
79
57
21
27
MA/I-binding CEA (u/ml)
s~~~~~~
<5
30
48
24
43
8
43
37
9
11
5-15
35
25
6
31
14
24
11
7
13
15-30
12
13
25
13
3
3
5
1
1
30-50
4
4
8
2
4
6
3
3
1
duce the same displacement. In
these results it was necessary to d
whether the radioimmunoassay d
with MA/l could measure MA/
CEA directly in the serum ofpati
cancer. To check this, and also
the type of cancers which could
tially followed on the monocloi
assay, random samples from
groups of patients were studiE
group included samples from pati
MA/I
units
>120 -* e.
110 _
901
701
501
30~
10
* 0
* * .
*
33+ve MA/I
<10 Abbott
0
0
00
0 _
000 0o
°°8° 00
42>10 Abbott
<15 MA/I
FIG. 1.-Chart showing assay values o:
serum specimens from a total c
samples from patients with colo
cancer, raised on the monoclonal
(MA/1) but < 10 ng/ml on the I
assay; and those raised on the I
assay (> 10 ng/ml) but < 15 u on the
assay. 78 of the 270 specimens (290/c
also raised on both assays and many c
showed discordant values (data not s]
view of early and metastatic cancer, but no data
letermine on the clinical status of the patients and
leveloped response to treatment were considered for
/1-binding this preliminary assessment. Like con-
ents with ventional CEA, MA/l-binding CEA was
to assess found to be associated with many forms
be poten- of cancer, but mainly with colo-rectal,
nal MA/l gastric and prostatic cancer (Table II). Of
several a further 71 samples from patients with
ed. Each other cancers, too varied to classify, 41%
ents with were raised, the main groups including
carcinoma of pancreas, urothelial cancer,
Abbott oesophageal cancer and cervical cancer.
values
ng/mI With the exception of gastric cancer, in
>150 which 57 % of 72 samples were raised, the
incidence of raised values for all other
o10 cancer groups was similar to that obtained
by measuring the same samples on the
90 Charing Cross routine assay.
Of 83 specimens from patients with
colo-rectal cancer, measured on both the
70 Charing Cross routine assay and the mono-
clonal assay, the incidences of raised
50 values were 33% and 30% respectively,
though the values for many of the speci-
30 mens differed. In particular, of the 83
specimens, 8 were raised on the mono-
clonal assay but < 10 ng/ml on the routine
10 assay, and 10 were raised (> 10 ng/ml) on
the routine assay but < 15 u/ml on the
If those monoclonal assay. 20% of the specimens
af 270 were raised on both assays, and a total of
,-rectal 42% were abnorm4l if both assays were
assay combined. Furthermore, of 31 additional
A~bbott
Abbott samples from patients with gastric cancer,
MA/I 22% were raised on the Charing Cross
were routine assay, whereas 51% were raised
f these
hown). on the monoclonal assay.
>50
14
12
8
3
5
3
1
1
1
0 % Raised
(> 15 u/ml)
31
29
57
19
35
15
16
24
11
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the MA/I assay values are exp
u/ml (see Materials and Methods
line represents upper limit norma
FiG. 2. Patients in Group
Comparative data on 270
samples from patients with
cancer, measured on the
Abbott diagnostic kit and
assay, have also shown that, a]
incidences of raised values w
for each assay (47% and 41% r(
some of the pairs of resul
markedly. Of the 270 sample
raised on the monoclonal
< 10 ng/ml on the Abbott ass
were raised on the Abbott
< 15 u/ml on the monoclonal
Serial 8tudies
Thirty-three patients with colo-rectal
cancer were followed serially on the
monoclonal, Charing Cross routine and
Abbott assays for circulating CEA. Four
main groups emerged from this study:
*urio Group A.-Six patients have progressed
favourably for at least 2 years after sur-
gical resection of their primary tumours,
and have shown no clinical evidence of
recurrence during the assessment period.
In 5 of these cases all 3 assay parameters
-4;9s:-f~ have remained below the clinical cut-off
limit during the follow-up .In the other
case (Fig. 2A) the monoclonal and Charing
Cross routine assays were transiently
raised 3 months and 7 months after
tumour resection, the latter rise correlat-
ing with adjuvant chemotherapy. Subse-
-iv';6T quent assay values on this patient have
remained below the clinical cut-off, con-
k*:- P; sistent with good clinical progress. One
patient in this group had a significantly
raised and rising y-glutamyltranspepti-
dase (GGT) level, indicating impaired
;,"4~^. liver function, despite normal levels of
circulating CEA and lack of evidence of
* !; tumour recurrence (Fig. 2B). snts with Group B.-Raised serum CEA levels
say; 40= -Abbott were encountered in 3 patients without
;s routine
il whereas
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any evidence of clinical recurrence during
the assessment period. In one case (Fig. 3)
the patient had a mucus-secreting adeno-
carcinoma ofthe pelvic colonwith omental
secondaries which responded to treatment,
and the patient was clinically clear 16
months later. During this period all 3
assays showed transient rises. This patient
died 2 months after the end of the study,
and had clinical evidence of recurrence
in the last month before his death. In the
other 2 patients the Abbott assay values
P.M. Female
CARCINOMA OF CAECUM WITH HEPATIC METASTASES
ERS ET AL.
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FIGS 4, 5, 6.-Patients in Group C.
were normal, whereas the Charing Cross
and monoclonal assays were consistently
raised over a period of several months.
Patiet /The significance of these responses is not
/died known. The 3 patients in this group had
normal y-glutamyltranspeptidase levels.
Twenty-four patients in this study
developed either recurrent or metastatic
tumours or both during the assessment
period, and these are considered in Groups
C andD.
Group C.-In 8 of these patients there
was a broad correlation between the
Mlonths monoclonal assay data and the results of
the two conventional assays (Figs 4 and 5).
In all cases progression of the disease and
ensuing metastases was accompanied by
a rising trend in the CEA values, though
the rise was not always steady. Lack of
samples precluded a detailed comparison
Patient of the onset of a positive value for each
died assay, but in 4 cases the monoclonal assay Chemti,wpyI
| was raised somewhat later than the other
two assays. One of these patients (Fig. 6)
is interesting, since despite the Charing
Cross routine and Abbott values being
raised during a period where recurrent
cancer was well controlled by chemo-
therapy, the monoclonal assay did not
1 respond until the patient developed an
intractable local recurrence in the pelvis
1/78 Months and the disease started to progress.
y-Glutamyltranspeptidase levels in all but
-.,
,:f. I
e.umedsIei.
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FIGs 7, 8.-Patients in Group D.
one of the patients in this grc
raised, correlating with metastati
into the liver.
Group D.-In 16 patients in th
progression of the tumour was
panied by only a partial assay i
In 7 of these cases the Abbott a
not markedly raised at any stag
disease, though marked transient
values were observed with ei
Charing Cross assay or the MA/I
both. For one of these patients,
assay correlated with a sym
pelvic recurrence of tumour, whei
the conventional assays were ni
at all. y-Glutamyltranspeptidase
this patient were only moderat
and there was no clinical evidenci
metastases. A marked transient
fall in the MA/I assay accompz
imminent death ofthe patient (Fi
a noteworthy feature of this g
some cases this type of patt
accompanied by a similar pattern in the
- .ntdh" Charing Cross assay (Fig. 7), or by arising
March M. CEA as measured in both conventional
assays. In 2 cases all 3 assays values have
x; remainedbelowthe cut-offlimit for atleast
18 months before death ofthe patient and
during a period of progressive tumour
invasion. In one of these cases the patient
showed no clinical signs of recurrence,
despite disseminated carcinomatosis
''" vr t; proven post mortem. The y-glutamyltrans-
peptidase levels in these patients were
low, probably reflecting minimal liver
involvement.
In the 9 cases in which the Abbott assay
was markedly raised, the general pattern
was a fairly steady increase in value with
Plinht d' progressing disease (Fig. 8). In 6 of these
'ti[nC ; cases a similar pattern was seen with the
Charing Cross assay (Fig. 8). However,
rising values on the conventional assays
in these patients were frequently accom-
panied by either no response or a transient ~. Z "ii^ change in the MA/I assay. In these cases
failure of the MA/I assay to reflect pro-
gressive tumour growth was usually
accompanied by a normal or only moder-
ately raised y-glutamyltranspeptidase
up were level, suggesting minimal liver involve-
ic spread ment, and the possibility that much of
the circulating CEA was originating from
1is study, sites other than the liver.
A accom-
response. DISCUSSION
,ssay was
ye of the As with the conventional CEA assays,
tly raised an arbitrary cut-off has been set on the
ther the monoclonal assay because of low levels of
assay or MA/l-binding CEA in serum from normal
the MA/I individuals. Further assessment of normal
ptomatic sera from a wider population and an
reas both extended age group may be warranted,
ot raised but exclusion of occult disease in elderly
levels in subjects is difficult. With an upper normal
tely high limit of 15 u/ml the overall false-positive
e of liver rate of the MA/I assay for non-malignant
rise and conditions was similar to that of the
anied by Charing Cross routine assay, in which
ig. 7) was non-malignant liver and colonic diseases
roup. In were the most common conditions produc-
tern was ing a raised value. However, the detailed
_ _ _ _ _ __-
-. I .1 & , *. | . v =. . ._ _ k. .s . . t:
.-2"7--
377G. T. ROGERS ET AL.
comparison between the MA/I and the
Charing Cross assays to measure non-
malignantdiseaserevealedmarkednumeri-
cal variations in the actual values which
are probably attributable to the differing
specificities of the two antisera. The asso-
ciation between raised CEA and chronic
renal failure is noteworthy. Raised con-
ventional CEA values associated with this
condition have been previously reported
in 37% of 27 patients with chronic renal
failure who lacked evidence of either
malignancy or other recognized non-
malignant cause of the elevation (Brand-
stetter et al., 1979). The reason for this is
obscure, but in view ofthe unlikelihood of
CEA or its immunologically active degra-
dation products normally being cleared by
the kidney, it could be attributed to an
increased synthesis of CEA or diminished
catabolism of the glycoprotein in these
patients. The response of the MA/I assay
and our routine assay to chronic renal
failure differ markedly, however. Whereas
the MA/I assay picks up 33% of 34 cases,
the Charing Cross assay responds in only
3%. This is an interesting observation for,
although we cannot completely exclude
malignancyfrom thepatientsinthisgroup,
it could reflect a radical difference in
specificity of these assays for at least one
non-malignant condition.
The finding of substantial amounts of
MA/i-binding CEA in the serum of
patients with cancer has substantiated
earlier evidence (Rogers et al., 1981) that
this monoclonal antibody detects a species
of CEA more prevalent in serum than in
tumour extracts. Other studies (Vrba
et al., 1975) have indicated that serum
CEA may differ chemically and immuno-
logically from CEA extracted from tumour
tissue. The use of conventional polyvalent
antisera may have previously obscured
this difference.
The MA/I assay did not differ markedly
from conventional CEA assays in its
specificity for cancers according to site of
origin. On the contrary, measurements on
samples from many groups have shown a
similar incidence of high values to that
encountered in the Charing Cross assay,
with the possible exception of gastric
cancer, thus warranting further assess-
ment ofthis group. The marked differences
in response of individual assays described
here for colo-rectal cancer, however, sup-
port the concept of differing immuno-
logical forms of CEA being expressed by
different patients. The different spectra of
positivity also suggest that an improved
detection rate may be possible by using
assays with several monoclonal antibodies
selectedfortheirspecific characteristics.
It is worth noting at this point that the
incidence of raised values (quoted in
Table II) for any given cancer group will
not necessarily agree with the statistics
of other laboratories, as this depends on
the particular samples assayed. The inci-
dence of positivity of preoperative CEA
levels is to some extent, depending on the
specificity of the assay, related to post-
operative staging of a tumour (Paone
et al., 1980). However, as our serial studies
on patients with colo-rectal cancer have
shown, the transitory nature of many
values would make it difficult in this study
to correlate progressing disease and inci-
dence of positivity in a meaningful way.
Serial studies on 33 patients with colo-
rectal cancer have permitted further
observations. The prognostic reliability
of a normal CEA level is not improved by
the MA/I assay. It failed to produce a
raised value at any stage of the disease in
7 patients with progressive cancer. By
comparison, the Abbott assay was mar-
ginally raised (5-10 ng/ml) in 8 cases of
progressive disease if a cut-off of 5 ng/ml
was chosen, but at these low values no
trend was seen. The Charing Cross assay
value was consistently normal in only 3
ofthe cases ofprogressive disease in Group
D. Where the value was raised it tended
to be a transient change and only 4/16
cases in this group displayed a steadily
rising trend. It may be concluded that the
colo-rectal tumours in this group express
different forms of CEA which are recog-
nized differently by each of the 3 assays.
Moreover, theresultsonindividualpatients
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show that different forms of CEA may be
expressed at different stages of the disease
and, unfortunately, this expression may
not correspond to tumour progression.
A correlation between the circulating
CEA level and progression of tumour
spread, as determined clinically, was
evident in the 8 cases of Group C, and
here all 3 assay trends appeared broadly
to correspond, though the MA/I assay
responded somewhat later than the con-
ventional assays in at least 4 cases. In
contrast, in Group D a rising trend in at
least one assay was found in only 8/16
cases. In most other cases there were
transient changes in the assay response.
These changes may reflect physiological
factors influencing the growth rate of
the tumour or biochemical manifestations
influencing the production of CEA, its
immunological expression or its appear-
ance in the circulation. The clinical sig-
nificance, ifany, ofthese transient changes
is obscure, though it has been noted that
trauma following, for instance, peritoneal
resection, can sometimes produce raised
circulating CEA levels in the weeks that
follow. The effects of chemotherapy could
be another factor influencing the transport
or detection of CEA in the circulation.
CONCLUSIONS
Despite the relative inability of the
monoclonal antibody MA/I to bind to
CEA extracted from tumour tissue, this
study has demonstrated the presence of
substantial amounts ofMA/l-binding CEA
in the serum of some patients with cancer.
Low levels are found in sera from normal
individuals and moderately high levels
are sometimes associated with certain
non-malignant diseases. As with the
conventional CEA assays, significantly
raised values are found in serum from
patients with a variety of solid tumours.
Direct comparisons between the mono-
clonal and conventional assays have
revealed marked differences in the actual
assay values, indicating differences in
specificity between the assays. The MA/I
assay appears to measure a different
population of CEA molecules or a subset
of those measured on both routine assays.
The results of serial measurements have
further suggested that patients may
express different immunological forms of
CEA in the course of tumour progression,
but no prognostic value was evident in
this preliminary study. The results of
this study stress the need to resolve the
immunological specificities expressed by
CEA-like molecules and evaluate their
clinical importance. The development of
monoclonal anti-CEA antibodies should
facilitate this task considerably.
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